Nanosphere Wins FDA Clearance to Market CYP2C19 Mutations Detection Test
Nanosphere, Inc. (Nasdaq: NSPH) announced today the US FDA granted 510(k) clearance permitting marketing of its CYP2C19 Nucleic Acid Test (CYP2C19 Test) on the automated sample-to-result Verigene^® System.
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.